The Hematology Department of Shenzhen Bao’an People's Hospital, established in 1998, is the only hematological specialty within the Bao’an health system. It serves as a postgraduate training site for Guangdong Medical University and undertakes undergraduate and graduate teaching for several universities, including Shenzhen University and Southern Medical University. The department is also one of the GIPAP/TIPAP medical centers affiliated with the China Charity Federation, a National Hemophilia Treatment Center, and a demonstration collaboration unit for the MPN standard diagnosis and treatment of the Chinese Anti-Cancer Association.
Following the completion of the hospital's second-phase renovation, the Hematology Department will have a total of 52 beds, with 33 currently in use. The department boasts a team of 10 doctors, including 1 chief physician, 2 deputy chief physicians, 6 attending physicians, and 1 resident physician. Among them, there is 1 doctoral student, 9 master's students, and 1 master's supervisor. Additionally, the department has an experienced nursing team.
The Hematology Department is a member of the South China Hematological Diseases Alliance, the Shenzhen Lymphoma Alliance, and the National Hemophilia Treatment Center. In 2024, the department's outpatient visits exceeded 10,000, with over 1,300 inpatient admissions. The main diseases treated include multiple myeloma, lymphoma, leukemia, myelodysplastic syndrome, immune thrombocytopenic purpura, and aplastic anemia. In 2013, the department introduced blood cell apheresis technology, significantly enhancing its rescue capabilities for hypercellular leukemia, chronic myeloproliferative neoplasms, and thrombotic thrombocytopenic purpura.
In 2023, Deputy Chief Physician Li Jianyun was sent to the First Affiliated Hospital of Zhejiang University School of Medicine for advanced studies in autologous and allogeneic hematopoietic stem cell transplantation. In 2024, the department successfully carried out autologous hematopoietic stem cell transplantation, with all patients experiencing no serious complications. Patients with lymphoma and multiple myeloma in our hospital can receive internationally standardized treatment.
After the second-phase renovation is completed, the Hematology Department will commence allogeneic hematopoietic stem cell transplantation, with 10 100-level laminar flow beds available. By then, patients with high-risk acute leukemia, myelodysplastic syndrome, severe aplastic anemia, and severe immunodeficiency will be able to receive treatment without needing to leave Bao’an.
In recent years, the department has collaborated with numerous authoritative hematology hospitals, such as NanFang Hospital Affiliated to Southern Medical University and Peking University People's Hospital, achieving remarkable results in basic and clinical research on thrombosis and hemorrhagic diseases, leukemia, MPN, and other diseases. These research findings have been published in international and domestic hematological journals, such as "Blood," "Leukemia," and "Chinese Journal of Hematology."
The Hematology Department of Bao'an People's Hospital ranks among the top in Shenzhen in terms of technical expertise, department size, and patient volume. The entire staff of the Hematology Department is dedicated to alleviating the pain of patients with their superb medical skills and warm services.
